Immunotherapy Coverage from Every Angle


Biweekly Dosing Approved by the FDA for Teclistamab-cqyv in Multiple Myeloma
CheckMate 722: Final Results With Nivolumab Plus Chemotherapy in Metastatic NSCLC
Atezolizumab Plus Chemotherapy in Advanced Urothelial Carcinoma: Final Overall Survival Analysis
Enfortumab Vedotin After Maintenance Avelumab in Advanced Urothelial Cancer
Phase III Trial of Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
Cardiac Health and Lung Cancer Treatments: A Complex Balancing Act for Oncologists
FDA Grants Accelerated Approval to Cellular Therapy for Unresectable or Metastatic Melanoma
DREAMM-7 Supports Novel Triplet Regimen in Relapsed or Refractory Multiple Myeloma
ASCO GU 2024: Molecular Trends in Urothelial Tumors With Microsatellite Instability
KEYNOTE-942: Neoantigen Therapy Plus Pembrolizumab in Resected Melanoma
ASCO GU 2024: Long-Term Survivorship With Adjuvant Nivolumab in Urothelial Carcinoma
Kidney Transplant Recipients: Immunotherapy Strategy for Cutaneous Squamous Cell Carcinoma
Initial Trial Results With Novel Combination Therapy for Resistant Myeloma
ASCO GU 2024: Updated Trial Data Support Immunotherapy Combination in Some Urothelial Carcinomas
Is First-Line Immunotherapy Efficacy Impacted by Race or Ethnicity in Advanced NSCLC?
Predicting Immunotherapy Responsiveness Based on T-Cell Expression in Patients With Advanced Skin Cancer
ASCO GU 2024: Phase III Trial of Pembrolizumab in Advanced Urothelial Cancer
FDA Calls for New Boxed Warning on All CAR T-Cell Therapies
ASCO GI 2024: IMbrave151 Update on Atezolizumab-Based Regimen in Biliary Tract Cancer
Early Results With Bispecific T-Cell Engager in High-Risk Smoldering Myeloma
NCCN Awards Grants to Study Use of BCMA-Directed Bispecific Antibody in Multiple Myeloma
Adjuvant Atezolizumab Plus Standard Chemotherapy in Triple-Negative Breast Cancer
MonumenTAL-1 Trial: Intensity of Dosing With Talquetamab in Myeloma Under Study

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.